Doubleblind
Enveric Biosciences dubs EB-002 as a “next-generation” psilocin pro-drug and aims to use it as a stepping stone for its future, trip-free psychedelic medications.
veryone is watching MAPS and Lykos Therapeutics to see whether the FDA will approve MDMA-assisted therapy for PTSD, and if Lykos will secure a patent for MDMA. But while all the attention has been on them, other biotech firms are doing something similar. Enveric Biosciences is currently waiting on the FDA to approve its psychedelic compound, EB-002, which it has also filed — and received — patents for, according to Green Market Report.
EB-002 is described as a “next-generation” psilocin pro-drug and is currently a candidate to become a medication for anxiety disorders. Psilocin is one of the major compounds in psilocybin mushrooms. In fact, psilocybin converts to psilocin in the digestive tract and is technically the molecule that produces the psychedelic experience.
Read the full report
Another Psychedelic Drug Derivative Secures Patent and Awaits FDA Approval
